Big Pharma rejoins the mental health field, WSJ says

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due companies distancing themselves from the field, David Wainer of The Wall Street Journal reports. Recently, signs of a cautious revival are emerging, with Bristol Myers Squibb (BMY), AbbVie (ABBV), and Johnson & Johnson (JNJ) each acquiring companies who are developing psychiatric drugs. The deals are, however, modest compared to pharma’s investments in oncology, autoimmune diseases, or the broader neurological field conditions, such as Alzheimer’s.